Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

AMGNAmgenRunning, no new patients

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

B Cell Precursor Acute Lymphoblastic Leukemia

2Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

  • 3 insiders sold shares within a month

    Since Aug 13, 2026 · was worth 5, fading over time

    +1.9
Worry score2

Score over time

Stage
Phase 1/2
Patients
181 (final count)
Started
Jan 4, 2021
Main results expected
Nov 24, 2027
Fully finished
May 25, 2029
Results posted
not yet

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Dose Escalation Phase: Number of participants who experience dose limiting toxicities (DLTs)

    Measured over: Up to 29 days

  • Dose Escalation Phase: Number of participants who experience one or more treatment-emergent adverse events (TEAEs)

    Measured over: Up to approximately 28 weeks

  • Dose Escalation Phase: Number of participants who experience one or more serious TEAEs

    Measured over: Up to approximately 28 weeks

  • Dose Escalation Phase: Number of participants who experience one or more treatment-related TEAEs

    Measured over: Up to approximately 28 weeks

  • Dose Escalation Phase: Number of participants who experience one or more adverse events (AEs) of Interest (AEIs)

    Measured over: Up to approximately 28 weeks

  • Dose Expansion and Phase 2 Ph-IIR cohort: Number of participants who achieve complete remission (CR) / complete remission with partial hematological recovery (CRh)

    Measured over: Up to 10 weeks

  • Phase 2 Ph-IIC cohort: Maximum concentration (Cmax) of blinatumomab SC1 and SC2

    Measured over: Up to approximately 4 weeks

  • Phase 2 Ph-IIC cohort: Average concentration (Cavg) of blinatumomab SC1 and SC2

    Measured over: Up to approximately 4 weeks

  • Phase 2 Ph-IIC cohort: Time to reach maximum concentration (Tmax) of blinatumomab SC1 and SC2

    Measured over: Up to approximately 4 weeks

  • Phase 2 Ph-IIC cohort: Area under the concentration-time curve (AUC) of blinatumomab SC1 and SC2

    Measured over: Up to approximately 4 weeks

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)

Raw record changes

  • none yet

Trial ID NCT04521231 · record last updated 2026-05-28 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT04521231) ↗

Phase 2 Ph-IIM cohort: Number of participants who achieve CR with MRD-negative response

Measured over: Up to 10 weeks